Question 1

What are the potential side effects of SCT200?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC clinical trial (NCT03405272). Contact the study team or your healthcare provider for specific answers.

Question 2

How does SCT200 compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC clinical trial (NCT03405272). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC clinical trial (NCT03405272). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or monitoring I will need while on this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC clinical trial (NCT03405272). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer progresses while I am participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC clinical trial (NCT03405272). Contact the study team or your healthcare provider for specific answers.

Question 6

Will my participation in this trial affect my eligibility for other treatments in the future?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC clinical trial (NCT03405272). Contact the study team or your healthcare provider for specific answers.

What this study is about